HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 7, July 2016 – Water Technology and Management       » World Toilet Organisation - Let's Talk about Toilets       » Recirculation Aquaculture Systems (RAS): An Opportunity for the SE Asian Aquaculture Industry       » Water Policy Response to Water Scarcity and Future Climate Change Impacts       » Burden of Thrombosis-related Diseases in Asia-Pacific       » Waste Management in Singapore: Where Does Our Rubbish Go?      
EYE ON CHINA
Biogen Idec and UCB enter agreements to develop and commercialize multiple sclerosis and hemophilia therapies in China and other parts of Asia
Biogen Idec and UCB have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

"Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible," said Carlos Dourado, Senior Vice President, Emerging Markets at Biogen Idec. "By leveraging UCB's extensive resources, expertise and infrastructure in Asia, we believe we can grow our footprint in critical Asian markets, get our therapies to patients more quickly and create a foundation for further commercial success in this region."

"As a patient centric biopharmaceutical company, UCB is delighted to work with Biogen Idec on delivering some of the most important breakthrough products in the treatment of multiple sclerosis and hemophilia to patients in Asia," said Mohamed Chaoui, Head of Asia Pacific at UCB. "This partnership is a strong complement in our goal to offer innovative specialty care therapeutic options to patients suffering from severe diseases. It further supports our strategic goal to strengthen our leadership and expertise in biologics in both neurology and immunology in China and the Asian region."

Mr. Chaoui added, "We are committed to strengthening our presence in Asia and offering patients and healthcare providers in the Asian region access to new and innovative treatment options. This agreement is also an important step for our specialty focused expansion in China. It will help drive our business growth in key emerging markets, which is one of UCB's top strategic priorities."

Click here for the complete issue.

NEWS CRUNCH  
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy